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Edited by Hans-Dieter KlenkAbstract Hepatitis C virus (HCV) replication and pathogenesis
involve both virus-encoded proteins and cellular factors. In our
study, we showed that NS5B, the HCV RNA-dependent RNA
polymerase, interacted with M2 type pyruvate kinase (M2PK)
but not L type pyruvate kinase. We conﬁrmed the interaction by
GST pull down, coimmunoprecipitation and confocal immunoﬂu-
orescence analysis in cells with transient expression of NS5B and
M2PKaswell as in aHCV replicon-bearing cell line. Furthermore
shRNA which speciﬁcally down-regulated M2PK expression
could inhibit the replication of HCV in HCV replicon 9B cells.
Structured summary:
MINT-6548876, MINT-6548924:
NS5B(Con1) (uniprotkb:Q9WMX2) and M2PK (uniprotkb:
P14618) colocalize (MI:0403) by ﬂuorescence microscopy
(MI:0416)
MINT-6548705:
NS5BD21(BK) (uniprotkb:P26663) physically interacts
(MI:0218) with M2PK (uniprotkb:P52480) by two hybrid
(MI:0018)
MINT-6548722, MINT-6548746:
CM2PK (uniprotkb:P52480) binds (MI:0407) to
NS5BD21(BK) (uniprotkb:P26663) by pull down (MI:0096)
MINT-6548831:
M2PK (uniprotkb:P14618) physically interacts (MI:0218) with
NS5B (Con1) (uniprotkb:Q9WMX2) by anti bait coimmuno-
precipitation (MI:0006)
MINT-6548795:
M2PK (uniprotkb:P14618) physically interacts (MI:0218) with
NS5B(Con1) (uniprotkb:Q9WMX2)by anti tag coimmunopre-
cipitation (MI:0007)
MINT-6548852:
M2PK (uniprotkb:P14618) and NS5BD21(BK) (uniprotkb:
P26663) colocalize (MI:0403) by ﬂuorescence microscopy
(MI:0416)
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Hepatitis C virus (HCV), a member of the positive-stranded
RNA viruses of the family Flaviviridae, is a major etiologic,
causative agent of non-A, non-B hepatitis worldwide. Its gen-
ome contains a single open reading frame of 9.6 kb that encodes
a large polyprotein precursor of about 3010 amino acids. After
translation by the host ribosome, the precursor is then pro-
cessed into ten distinct proteins (C, E1, E2, p7, NS2, NS3,
NS4A, NS4B, NS5A and NS5B). NS5B is the viral RNA-
dependent RNA polymerase (RdRp) that contains motifs
shared by all RdRps, including the active site Gly-Asp-Asp se-
quence, which is believed to bind magnesium ions and is essen-
tial for enzymatic activity [1]. It has a highly hydrophobic C-
terminal region that is responsible for membrane anchoring
[2,3]. Deletion of the C-terminal 21 residues facilitates NS5B
solubility during Escherichia coli expression and still retains
the RdRp activity [4]. NS5B is believed to form a membrane-
associated RNA replication complex together with other non-
structural proteins, NS3, NS4A, and NS5A [5,6] and as yet
unidentiﬁed host components. NS5B has been reported to
interact with some cellular factors, such as a SNARE-like pro-
tein [7], a ubiquitin-like protein [8], nucleolin [9], human eIF4a
[10], a-actinin [11], RNA helicase p68 [12] and cyclophilin B
[13–15]. Although some of them have been proved to function-
ally regulate HCV replication, until now little is known about
components of the HCV replication complex.
In current study, we attempted to identify novel cellular pro-
teins that interact with the HCV NS5B and reveal its potential
roles in HCV replication. We showed that HCV NS5B could
associate speciﬁcally with M2 type pyruvate kinase (M2PK)
but not with other isoforms of pyruvate kinase. Down-regula-
tion of M2PK expression could inhibit the replication of HCV
genome.2. Materials and methods
2.1. Plasmids
The mouse embryo cDNA library used in yeast two-hybrid screening
was described previously [16]. Fragment NS5BD21 (deletion of C-ter-
minal 21 amino acids) of HCV strain BK was cloned from plasmid
pET21b-NS5BD21 [17] into pGBKT7, pM and pEGFPC1 (Clontech)
vectors to get constructs: pBD-NS5BD21, pM-NS5BD21 and pGFP-
NS5BD21. Full-length cDNA fragment for NS5B was ampliﬁed from
plasmid pFK1-9605/Con1 (HCV Con1 strain, kindly provided by R.
Bartenschlager, Universita¨tsklinikum Heidelberg, Germany) and then
cloned into pEGFPC1 vector to get pGFP-NS5B construct. The
NS5BD21 of strain BK has a diﬀerence of 21 amino acids from the
corresponding region of NS5B of HCV strain Con1. Sequences
encoding the full-length human M2PK (aa 1–531), L type pyruvateation of European Biochemical Societies.
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531) were ampliﬁed by PCR using cDNA from Huh7 cells and then
cloned into plasmid pGADT7, pVP16 (Clontech) and pGEX-4T-1
(Amersham Pharmacia Biotech) to obtain constructs: pAD-M2PK,
pAD-CM2PK, pVP16-M2PK, pVP16-LPK, pGEX-M2PK and
pGEX-CM2PK. Plasmid pFLAG-M2PK was obtained by inserting
fragment M2PK into pCMV-Tag2B vector (Stratagene). Plasmids
pHA-M2PK, pHA-CM2PK, pHA-LPK and pHA-NS5B were gener-
ated by inserting coding sequences of M2PK, CM2PK, LPK and
NS5B into pCI-Neo (Promega) with an ATG-HA-tag at the N termi-
nus. Reporter plasmids pLuc-M2PK and pLuc-LPK were constructed
by inserting M2PK and LPK gene into pLucN3 vector [18] so that they
can be used for screening speciﬁc siRNA to M2PK but not to LPK by
luciferase assays. Based on the siRNA design tools (http://www.ambi-
on.com), four targeting sites of M2PK were selected: shM2PK-1,
TAGGCGTTATCCAGCGTGATT; shM2PK-2, CAG-
GATGTTCTCGTCACACTT; shM2PK-3, TTCCACCACCTTGCA-
GATGTT; shM2PK-4, CCCATCATCCACGTAGATCTT. The
corresponding DNA sequences were inserted between BamHI and
HindIII sites of pSilencer-H1 (3.0) vector (Ambion, USA). Control
plasmid pLucR was described previously [19].
2.2. Glutathione-S-transferase (GST) pull-down assays
Plasmids pET21b-NS5BD21, pGEX-4T-1, pGEX-M2PK and
pGEX-CM2PK were transformed and expressed in E. coli BL21
(DE3) cells as described previously [17,20]. GST fusion proteins
(GST-M2PK and GST-CM2PK) or GST as control were incubated
with glutathione-sepharose beads (Promega), and then mixed with
His-NS5BD21 protein in phosphate-buﬀered saline (PBS). After rock-
ing for 3 h at 4 C, the beads were washed three times with PBS and
then subjected to SDS–PAGE/immunoblot analysis by using either
anti-GST (NeoMarkers) or anti-NS5B antibody (Santa Cruz Biotech-
nology).
2.3. Coimmunoprecipitation
293T cells (1 · 107 cells) transfected with plasmid pairs pFLAG-
M2PK/pHA-NS5B were washed three times with ice-cold PBS and sol-
ubilized with 1 ml RIPA buﬀer (20 mM Tris–HCl pH 7.5, 100 mM
NaCl, 0.5% NP-40, 0.5 mM EDTA, 0.5 mM PMSF, 0.5% protease
inhibitor cocktail [Sigma]). Detergent-insoluble materials were re-
moved by centrifugation at 14000·g for 15 min at 4 C. After incuba-
tion with anti-FLAG antibody (NeoMarkers) on a rocker for 2 h at
4 C, the whole cell lysate was mixed with 100 ll of pre-equilibrated
protein G plus/protein A-agarose beads (Calbiochem) and rocked for
1 h at 4 C to capture the immunocomplex. The beads were then col-
lected by centrifugation and gently washed three times with PBS.
The bound proteins were analyzed by SDS–PAGE/immunoblot with
an anti-NS5B antibody (Protein Tech Group) and anti-FLAG anti-
body. For 9-13 cells [21], lysates were subjected to immunoprecipita-
tion with anti-M2PK antibody (Protein Tech Group) or rabbit
normal sera and then Western blot analysis with anti-NS5B antibody
and anti-M2PK antibody.
2.4. Confocal immunoﬂuorescence microscopy
COS7 cells cultured on 25-mm coverslips were transfected with indi-
cated plasmids. At 24 h after transfection, the cells were ﬁxed with 4%
formaldehyde in PBS, permeabilized with 0.2% Triton X-100 in PBS
and blocked with 5% BSA in PBS for 4 h at 37 C. Samples were then
incubated with rabbit anti-HA antibodies (NeoMarkers) for 1 h. After
washing three times with PBS, samples were then incubated with
TRITC-conjugated goat anti-rabbit IgG (Sigma) for 50 min. After fur-
ther washing, coverslips were ﬁnally mounted on glass slides and cells
were observed under a Leica TCS-NT confocal microscope. For 9–13
cells, samples in Fig. 2A was probed with anti-NS5B antibody and
then visualized by FITC-conjugated rabbit anti-goat IgGs (Sigma)
and samples in Fig. 2E were probed with anti-NS5B antibody and
anti-M2PK antibody, and then visualized by TRITC-conjugated don-
key anti-rabbit IgGs and FITC-conjugated donkey anti-goat IgGs
(Sanying Biotechnology Inc.).2.5. RNA analysis
Total cellular RNA was isolated using TRIZOL reagent (Invitrogen)
according to the manufacturers protocol. One-tenth of each RNA
sample from a 35-mm well was reverse-transcribed with oligo dT (Pro-mega) using the Moloney murine leukemia virus (MMLV) reverse
transcriptase (Promega). Cellular glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA from the same cell lysate was used as
an internal control for cell number and metabolic status. Thirty-ﬁve
cycles of PCR were performed with cycling conditions of 30 s at
94 C, 30 s at 58 C and 45 s at 72 C.3. Results
3.1. Identiﬁcation of pyruvate kinase as a cellular target for
HCV NS5B
Using HCV NS5B lacking the C-terminal transmembrane
domain (NS5BD21) as bait in a yeast two-hybrid screening,
three clones located at the C-terminus of mouse M2PK (aa
333–531, 337–531, 345–531) were obtained. This region over-
lapped with the regulatory C domain of M2PK (aa 388–530),
where there is a diﬀerence of only four amino acids between
human and mouse M2PK. The interaction of HCV NS5BD21
with the C-terminus of mouse M2PK (mCM2PK) (aa 333–
531), its corresponding domain of human M2PK (CM2PK)
(aa 333–531) or the full length of human M2PK (aa 1-531)
was detected for b-Gal activity in yeast two-hybrid assays
(Fig. 1A). Results showed that both mCM2PK and CM2PK in-
duced a high b-Gal activity when co-transfected with
NS5BD21, while the value of the full length human M2PK
was comparatively low but was more than two times above neg-
ative controls. These results indicated that HCV NS5B could
interact with both human and mouse M2PK in yeast cells.
Low read-out value for full-length M2PK may reﬂect improper
folding or existence of inhibition domains in N-terminus of
M2PK, thus attenuating its interaction with HCV NS5B in
yeast cells. As HCV is a human virus, all the following experi-
ments were carried out with human pyruvate kinases.
To validate the association of HCV NS5B with M2PK, sev-
eral methods were adopted. First, an in vitro GST pull-down
assay was performed using the recombinant proteins His-
NS5BD21, GST-M2PK and GST-CM2PK. The results showed
that NS5BD21 protein was pulled down by both GST-CM2PK
(Fig. 1B, lane 1 in upper panel) and GST-M2PK in vitro (Fig.
1B, lane 2 in upper panel) but not by GST as a control protein
(Fig. 1B, lane 3 in upper panel). These results suggested that
NS5BD21 could interact directly with M2PK in vitro.
To gain further proof of this interaction, HA-NS5B and
FLAG-M2PK were coimmunoprecipitated with an anti-
FLAG antibody from 293T cells and analyzed by Western
blotting with an anti-NS5B antibody and anti-FLAG antibody
(Fig. 1C). Results showed that HA-NS5B was eﬃciently coim-
munoprecipitated with FLAG-M2PK (Fig. 1C, lane 2). Here,
the NS5B gene came from HCV Con1 strain instead of HCV
BK strain of NS5BD21 since all the HCV replicon cell lines
we used later were derived from HCV Con1 strain [21,22].
The in vivo interaction between NS5B and M2PK was fur-
ther tested by coimmunoprecipitation using 9–13 cells carrying
a replicating HCV replicon. As shown in Fig. 1D, M2PK was
speciﬁcally co-precipitated with NS5B in cellular extracts from
9–13 cells. Taken together, M2PK could form a complex with
NS5B protein both in vitro and in vivo.
3.2. Relocalization of M2PK through interaction with HCV
NS5B
We further analyzed the intracellular distribution and local-
ization of M2PK and HCV NS5B by confocal microscopy.
Fig. 1. Identiﬁcation of M2PK as a cellular target for HCV NS5B. (A)
Interaction of NS5B and M2PK in yeast two-hybrid system. After
cotransformation of diﬀerent plasmid pairs, b-Gal activity was
measured in yeast cellular extracts. 1. pBD-T+pAD-53 (positive
control); 2. pBD-NS5BD21+pAD-mCM2PK; 3. pBD-NS5BD21+
pAD-CM2PK; 4. pBD-NS5BD21+pAD-M2PK; 5. pBD-NS5BD21+
pAD-53; 6. pBD-T+pAD-M2PK and 7. pBD-T+pAD-Lam. Plasmid
pairs of columns 5–7 were used as negative controls. (B) In vitro pull-
down assays for analyzing the interaction between NS5BD21 and
M2PK. The His-NS5BD21 was mixed with GST-CM2PK (lane 1),
GST-M2PK (lane 2) and GST (lane 3 as negative control), respec-
tively, and the pull-down mixtures were analyzed in immunoblot with
anti-NS5B antibody (upper part) or GST antibody (lower part). (C)
Coimmunoprecipitation of NS5B with M2PK in 293T cells. The 293T
cells co-transfected with constructs expressing HA-NS5B and FLAG-
M2PK was subjected to immunoprecipitation (IP) with anti-FLAG
antibody or rabbit normal sera and Western blot (WB) assay with anti-
NS5B antibody (top) and with anti-FLAG antibody (bottom). Lane 1:
Total co-transfected cell lysates without immunoprecipitation, which is
equivalent to 1/24 of the amount of cell lysate used for immunopre-
cipitation in lanes 2 and 3; lane 2, immunoprecipitation with anti-
FLAG antibody; lane 3, immunoprecipitation with rabbit normal sera.
(D) In vivo coimmunoprecipitation of NS5B with M2PK in replicon
cell line 9–13. The lysates of 9–13 cells were incubated with an anti-
M2PK antibody and the immuno-complexes were probed with an anti-
NS5B antibody (top) and with an anti-M2PK antibody (bottom). Lane
1: total cell lysate of replicon 9–13 cells without immunoprecipitation,
which is equivalent to 1/24 of the amount of cell lysate input used for
immunoprecipitation; lane 2: immunoprecipitation of 9–13 cell lysate
with anti-M2PK antibody; lane 3: immunoprecipitation of 9–13 cell
lysate with rabbit normal sera; lane 4, immunoprecipitation of naive
Huh7 cell lysate with anti-M2PK antibody.
Fig. 2. Immunofuorescence analysis of NS5B-M2PK colocalization.
Panel A shows the subcellular distribution of HA-M2PK (left) and
GFP-NS5BD21 (middle) in COS7 cells and the NS5B in HCV replicon
9–13 cells (right). Panel B shows the cotransfection of HA-M2PK and
GFP-NS5BD21 while panel C represents the cotransfection of HA-
M2PK and GFP as a control. Panel D shows the cotransfection of
HA-M2PK and GFP-NS5B. Panel E represents confocal immunoﬂu-
orescence by probing endogenous M2PK and NS5B in 9–13 replicon
cells. (magniﬁcation ·400).
X. Wu et al. / FEBS Letters 582 (2008) 2155–2160 2157The results showed that M2PK displayed diﬀused distribution
in cytoplasm (Fig. 2A, left panel) and NS5BD21 protein was
predominantly localized in the nuclei (Fig. 2A, middle panel)
while the full-length NS5B expressed from HCV replicon in9–13 cells was mainly located in the endoplasmic reticulum
(ER) (Fig. 2A, right panel) as already demonstrated previously
[3,12,20]. Since the distribution patterns of M2PK, NS5BD21
and full-length NS5B are clearly diﬀerent, physical association
of the two proteins would lead to relocalization of at least one
protein of them. To prove this hypothesis, we transiently high-
expressed GFP-NS5BD21 and HA-M2PK protein in COS7
cells and the results showed that M2PK eﬃciently pulled the
NS5BD21 from nuclei into cytoplasm and then colocalized
(Fig. 2B). COS7 cells co-transfected with plasmid pair pHA-
M2PK/pGFPC1 were used as a negative control (Fig. 2C).
As NS5BD21, which lacks the C-terminal transmembrane
domain and has diﬀerent distribution from that of full-length
2158 X. Wu et al. / FEBS Letters 582 (2008) 2155–2160NS5B in vivo, was used here for the relocalization of the
proteins, the results only indicate that M2PK could bind and
relocalize NS5BD21. Therefore, for addressing whether
M2PK or NS5B is relocalized in vivo, full-length NS5B should
be used for relocalization assays.
Next, plasmids HA-M2PK and GFP-NS5B were transiently
co-transfected in COS7 cells. Colocalization analysis showed a
perinuclear overlapping in the intracellular distributions of
both proteins (Fig. 2D). Furthermore, with a HCV RNA rep-
licon that expresses all the non-structural proteins, we showed
relocalization of at least a portion of M2PK which was then
visibly colocalized with NS5B (Fig. 2E). Collectively, these re-
sults showed that human M2PK was a cellular partner for
HCV NS5B and the interaction between them resulted in relo-
calization of M2PK by interaction with full-length NS5B.
3.3. Isoform-speciﬁc interaction of PKs with HCV NS5B
There are four cell/tissue-speciﬁc isoforms of pyruvate ki-
nases: M1PK (skeletal muscles, brain and heart), M2PK (early
fetal and tumor tissues), LPK (liver and kidney) and RPK
(erythrocytes) [23,24]. To assay for the production of LPK
and M2PK in both naive Huh7 cells and 9–13 replicon cells,
we measured the amount of LPK and M2PK RNA after
ampliﬁcation through semiquantitative RT-PCR. The result
showed both LPK and M2PK were expressed in Huh7 cells,
but LPK was signiﬁcantly reduced in replicon cell line 9–13
(Fig. 3A, upper panel), and M2PK basically had no change
(Fig. 3A, middle panel).Fig. 3. Isoform-speciﬁc interaction of PKs and HCV NS5B. (A)
Expression of M2PK and LPK by RT-PCR analysis. The RNA for
M2PK and LPK was ampliﬁed from naive Huh7 and 9–13 replicon cell
lines. The cellular GAPDH RNA was similarly ampliﬁed as internal
control. (B) Mammalian two-hybrid assays of the interactions between
NS5B and PKs. Diﬀerent pairs of plasmids were co-transfected with the
reporter plasmid pG5Luc into 293T cells: 1. pM-NS5BD21+pVP16-
M2PK; 2. pM-NS5BD21+pVP16-LPK; 3. pM-NS5BD21+pVP16; and
4. pM+pVP16. 48 h after transfection, the reporter luciferase activity
was measured. (C) Confocal analysis of the cellular localization of LPK
and NS5BD21. The localization of HA-LPK with anti-HA antibody
were shown in the left panel and those of GFP-NS5BD21 were shown in
the right panel, while the merged images of the left and right panels
were shown in the middle panel.The LPK shares about 71% amino acids identity and very
similar three-dimensional structures with M2PK [25]. We em-
ployed mammalian two-hybrid system to analyze the interac-
tion between NS5BD21 and these two diﬀerent PK isoforms.
The results showed that co-transfection of NS5BD21 with
M2PK, but neither LPK nor various negative controls, could
signiﬁcantly increase the reporter activity in 293T cells (Fig.
3B).
To further conﬁrm this isoform-speciﬁc interaction, we co-
transfected plasmid pair pHA-LPK/pGFP-NS5BD21 into
COS7 cells. At 24 h after cotransfection, LPK and NS5BD21
were distributed independently (Fig. 3C). In contrast, M2PK
could pull NS5BD21 from nucleus into cytoplasm as shown
earlier in Fig. 2B. Taken together, we concluded that the
HCV NS5B could associate with a tumor-speciﬁc isoform of
pyruvate kinases (M2PK), but not with liver-speciﬁc isoform
of pyruvate kinase (LPK).
3.4. Knockdown of M2PK reduces the synthesis of HCV genome
in HCV replicon cells
The next question to be addressed is the biological function
of M2PK-NS5B interaction in HCV replication. We under-
took siRNA strategy to speciﬁcally inhibit the expression of
endogenous M2PK in the HCV 9B cell line which harbors a
HCV replicon with a luciferase reporter [22]. Since LPK and
M2PK shares about 70% nucleotide identity and are co-ex-
pressed in 9–13 replicon cells (Fig. 4A), we had to screen
shRNA that is speciﬁc to M2PK but has no inhibitory eﬀect
on the expression of LPK. ShM2PK-3 was a very potent inhib-
itor of M2PK and had no eﬀect on LPK as assayed by reporter
systems (Fig. 4A). Then we assayed the shRNA eﬃciency on
inhibiting the expression of endogenous M2PK by Western
blotting. Compared with both mock-transfected cells and
LucR (a control shRNA) transfected cells, the M2PK level
had decreased in cells transfected with plasmid shM2PK-3
(Fig. 4B), indicating that shM2PK-3 could speciﬁcally down-
regulate M2PK at protein level.
Finally, we transfected shM2PK-3 into HCV 9B cells which
harbor an HCV replicon carrying a luciferase reporter and
measured the luciferase activity at 48 h post-transfection. As
shown in Fig. 4C, the shM2PK-3 reduced the luciferase activ-
ity signiﬁcantly when compared with the cells transfected with
control LucR or mock.
To test whether pyruvate kinase activity plays a role in this
process, HCV 9B cells were transfected with empty vector,
LPK, M2PK and CM2PK, respectively. The results showed
that the HCV RNA synthesis was not aﬀected in the presence
of LPK and M2PK but was decreased when CM2PK was
overexpressed (Fig. 4D). The presence of the truncated
M2PK (CM2PK) without pyruvate kinase activity may com-
pete with full-length M2PK for interaction with HCV NS5B
and thus reduced the synthesis of viral RNA replication in
the dominant-negative manner. In conclusion, M2PK may
be involved in HCV RNA synthesis by direct interaction with
NS5B and its enzyme activity may be helpful for sustaining
HCV replication.4. Discussion
In current study, we identiﬁed a tumor-speciﬁc pyruvate ki-
nase (M2PK) as a novel cellular partner of HCV NS5B. M2PK
Fig. 4. Down-regulation of M2PK by shRNA and its eﬀect on HCV replicon replication. (A) Reporter plasmid pLuc-M2PK and pLuc-LPK
containing fusion sequences of ﬁreﬂy luciferase and M2PK or LPK were co-transfected respectively with each shRNAs into Huh7 cells and the
luciferase readout correlated with the inhibitory eﬀect of shRNAs on their speciﬁc target sequences. ShRNA LucR was used as a negative control. (B)
Western blotting was employed to analyze the inhibitory eﬀect of the shM2PK-3 on endogenous M2PK expression in Huh7 cells with LucR as
negative control (left). The densitometric quantitation of the protein bands was shown in the right. (C) Speciﬁc inhibition of HCV replicon
replication by M2PK shRNAs in HCV 9B cell line. HCV 9B replicon cells were transfected with empty vector, shM2PK-3 or LucR in 96 well plates
and the luciferase activity that was driven by HCV replicon was examined 48 h later. (D) Inﬂuence of overexpression of diﬀerent forms of pyruvate
kinases on HCV replicon replication. HCV 9B cells were transfected with empty vector, pHA-M2PK, pHA-LPK, or pHA-CM2PK, and assayed for
luciferase activity 48 h later.
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placed by the other tissue speciﬁc isoform: LPK (liver and kid-
ney), M1PK (skeletal muscles, brain and heart) and RPK
(erythrocytes) during development and re-expressed when cells
de-diﬀerentiate to become malignant [23,24]. Our results indi-
cated that HCV NS5B speciﬁcally interacted with M2PK but
not with LPK. Along with an isoform shift from LPK expres-
sion to M2PK at a late stage of the hepatocarinogenic process
and an increase both in activity and amount of M2PK in hepa-
tocellular tumors [26], M2PK may interact with HCV NS5B
protein and thus enhance the replication of HCV. M2PK
was also shown to be directly targeted by certain viral onco-
proteins, such as the activated pp60v-src kinase and the
HPV-16 E7 oncoprotein [23,24].
It has been reported that only a minor fraction of the HCV
NS5B is actively involved in RNA synthesis in HCV replicon
system [27]. Although it is not clear whether M2PK interacts
with the NS5B associated with replication complex or with
the majority of NS5B which is not directly involved in RNA
synthesis or with both, the interaction of M2PK with NS5B
is most likely relevant to HCV RNA synthesis because
down-regulation of M2PK expression could inhibit the replica-
tion of HCV replicon (Fig. 4).
Until now, all HCV replicon cells and replication systems
were constructed on human hepatocarcinoma cell line Huh7,
in which mostly LPK had already shifted into M2PK.
Although several attempts have been undertaken to cultureprimary human hepatocytes isolated from persistently infected
patients for HCV replication, their eﬃciency was low [28].
Therefore, it is tempting to suggest that diﬀerent types of pyru-
vate kinases may inﬂuence HCV replication diﬀerently and the
transition from LPK to M2PK may thus promote HCV gen-
ome replication. Although attempts to culture HCV with pri-
mary hepatocytes in vitro were unsuccessful, HCV replicates
eﬃciently in vivo in normal liver tissues where the hepatocytes
do not express M2PK. Therefore, it can be proposed that the
interaction of M2PK with NS5B might not be absolutely
essential for HCV replication but could enhance its eﬃciency
as shown in this study. However, normal liver tissues do con-
tain many cell types other than hepatocytes, such as sinusoidal
lining cells, hepatic artery smooth muscle, bile duct epithelium
and hepatic artery endothelium, which express strong or mod-
erate levels of M2PK but LPK [26]. Therefore, roles of these
cell types and M2PK in HCV replication in normal liver tissues
could not be excluded. Further studies are needed to reveal the
molecular mechanism for potential involvement of M2PK in
HCV RNA replication.
Acknowledgements: The authors thank Dr. Ralf Bartenschlager (Uni-
versita¨tsklinikum Heidelberg, Germany) for kindly providing the
HCV replicon cell lines and Dr. Weidong Zhong (Ribapharm Inc.,
US) for providing plasmid pET21b-NS5BD21. This work was sup-
ported by China National Science Foundation (#30570394), National
Basic Research Program of China (#2006CB504300) and the MOE
‘‘111’’ Project #B06018.
2160 X. Wu et al. / FEBS Letters 582 (2008) 2155–2160References
[1] Miller, R.H. and Purcell, R.H. (1990) Hepatitis C virus shares
amino acid sequence similarity with pestiviruses and ﬂaviviruses
as well as members of two plant virus supergroups. Proc. Natl.
Acad. Sci. USA 87, 2057–2061.
[2] Ivashkina, N., Wolk, B., Lohmann, V., Bartenschlager, R., Blum,
H.E., Penin, F. and Moradpour, D. (2002) The hepatitis C virus
RNA-dependent RNA polymerase membrane insertion sequence
is a transmembrane segment. J. Virol. 76, 13088–13093.
[3] Schmidt-Mende, J., Bieck, E., Hugle, T., Penin, F., Rice, C.M.,
Blum, H.E. and Moradpour, D. (2001) Determinants for mem-
brane association of the hepatitis C virus RNA-dependent RNA
polymerase. J. Biol. Chem. 276, 44052–44063.
[4] Yamashita, T., Kaneko, S., Shirota, Y., Qin, W., Nomura, T.,
Kobayashi, K. and Murakami, S. (1998) RNA-dependent RNA
polymerase activity of the soluble recombinant hepatitis C virus
NS5B protein truncated at the C-terminal region. J. Biol. Chem.
273, 15479–15486.
[5] Dimitrova, M., Imbert, I., Kieny, M.P. and Schuster, C. (2003)
Protein–protein interactions between hepatitis C virus nonstruc-
tural proteins. J. Virol. 77, 5401–5414.
[6] Shimakami, T., Hijikata, M., Luo, H., Ma, Y.Y., Kaneko, S.,
Shimotohno, K. and Murakami, S. (2004) Eﬀect of interaction
between hepatitis C virus NS5A and NS5B on hepatitis C virus
RNA replication with the hepatitis C virus replicon. J. Virol. 78,
2738–2748.
[7] Tu, H., Gao, L., Shi, S.T., Taylor, D.R., Yang, T., Mircheﬀ,
A.K., Wen, Y., Gorbalenya, A.E., Hwang, S.B. and Lai, M.M.
(1999) Hepatitis C virus RNA polymerase and NS5A complex
with a SNARE-like protein. Virology 263, 30–41.
[8] Gao, L., Tu, H., Shi, S.T., Lee, K.J., Asanaka, M., Hwang, S.B.
and Lai, M.M. (2003) Interaction with a ubiquitin-like protein
enhances the ubiquitination and degradation of hepatitis C virus
RNA-dependent RNA polymerase. J. Virol. 77, 4149–4159.
[9] Hirano, M., Kaneko, S., Yamashita, T., Luo, H., Qin, W.,
Shirota, Y., Nomura, T., Kobayashi, K. and Murakami, S. (2003)
Direct interaction between nucleolin and hepatitis C virus NS5B.
J. Biol. Chem. 278, 5109–5115.
[10] Kyono, K., Miyashiro, M. and Taguchi, I. (2002) Human
eukaryotic initiation factor 4AII associates with hepatitis C virus
NS5B protein in vitro. Biochem. Biophys. Res. Commun. 292,
659–666.
[11] Lan, S., Wang, H., Jiang, H., Mao, H., Liu, X., Zhang, X., Hu,
Y., Xiang, L. and Yuan, Z. (2003) Direct interaction between
alpha-actinin and hepatitis C virus NS5B. FEBS Lett. 554, 289–
294.
[12] Goh, P.Y., Tan, Y.J., Lim, S.P., Tan, Y.H., Lim, S.G., Fuller-
Pace, F. and Hong, W. (2004) Cellular RNA helicase p68
relocalization and interaction with the hepatitis C virus (HCV)
NS5B protein and the potential role of p68 in HCV RNA
replication. J. Virol. 78, 5288–5298.
[13] Watashi, K., Ishii, N., Hihikata, M., Inoue, D., Murata, T.,
Miyanari, Y. and Shimotohno, K. (2005) Cyclophilin B is a
functional regulator of hepatits C virus RNA polymerase. Mol.
Cell 19, 111–122.[14] Flisiak, R., Dumont, J.M. and Crabbe´, R. (2008) Cyclophilin
inhibitors in hepatitis C viral infection. Expert Opin. Inv. Drugs
10, 1345–1354.
[15] Paeshuyse, J., Kaul, A., Clercq, E.D., Rosenwirth, B., Dumont,
J.M., Bartenschlager, R. and Neyts, J. (2006) The non-immuno-
suppressive cyclosporine DEBIO-025 is a potent inhibitor of
hepatitis C virus replication in vitro. Hepatology 43, 761–770.
[16] Vojtek, A.B., Hollenberg, S.M. and Cooper, J.A. (1993) Mam-
malian Ras interacts directly with the serine/threonine kinase Raf.
Cell 74, 205–214.
[17] Zhong, W., Ferrari, E., Lesburg, C.A., Maag, D., Ghosh, S.K.,
Cameron, C.E., Lau, J.Y. and Hong, Z. (2000) Template/primer
requirements and single nucleotide incorporation by hepatitis C
virus nonstructural protein 5B polymerase. J. Virol. 74, 9134–
9143.
[18] Ishaq, M., Hu, J, Wu, X., Fu, Q., Yang, Y., Liu, Q. and Guo, D.
(2008) Knockdown of cellular RNA helicase DDX3 by short
hairpin RNAs suppresses HIV-1 viral replication without induc-
ing apoptosis. Mol. Biotechnol. doi:s12033-008-9040-0.
[19] Li, Z., Xiong, Y., Peng, Y., Pan, J., Chen, Y., Wu, X., Hussain,
S., Tien, P. and Guo, D. (2005) Speciﬁc inhibition of HIV-1
replication by short hairpin RNAs targeting human cyclin T1
without inducing apoptosis. FEBS Lett. 579, 3100–3106.
[20] Garcia-Gonzalo, F.R., Cruz, C., Munoz, P., Mazurek, S.,
Eigenbrodt, E., Ventura, F., Bartrons, R. and Rosa, J.L. (2003)
Interaction between HERC1 and M2-type pyruvate kinase. FEBS
Lett. 539, 78–84.
[21] Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L.
and Bartenschlager, R. (1999) Replication of subgenomic hepa-
titis C virus RNAs in a hepatoma cell line. Science 285, 110–113.
[22] Frese, M., Barth, K., Kaul, A., Lohmann, V., Schwa¨rzle, V. and
Bartenschlager, R. (2003) Hepatitis C virus RNA replication is
resistant to tumour necrosis factor-a.J. Gen. Virol. 84, 1253–1259.
[23] Zwerschke, W., Mazurek, S., Massimi, P., Banks, L., Eigenbrodt,
E. and Jansen-Durr, P. (1999) Modulation of type M2 pyruvate
kinase activity by the human papillomavirus type 16 E7
oncoprotein. Proc. Natl. Acad. Sci. USA 96, 1291–1296.
[24] Presek, P., Reinacher, M. and Eigenbrodt, E. (1988) Pyruvate
kinase type M2 is phosphorylated at tyrosine residues in cells
transformed by Rous sarcoma virus. FEBS Lett. 242, 194–198.
[25] Wooll, J.O., Friesen, R.H., White, M.A., Watowich, S.J., Fox,
R.O., Lee, J.C. and Czerwinski, E.W. (2001) Structural and
functional linkages between subunit interfaces in mammalian
pyruvate kinase. J. Mol. Biol. 312, 525–540.
[26] Hacker, H.J., Steinberg, P. and Bannasch, P. (1998) Pyruvate
kinase isoenzyme shift from L-type to M2-type is a late event in
hepatocarcinogenesis induced in rats by a choline-deﬁcient/DL-
ethionine-supplemented diet. Carcinogenesis 19, 99–107.
[27] Quinkert, D., Bartenschlager, R. and Lohmann, V. (2005)
Quantitative analysis of the hepatitis C virus replication complex.
J. Virol. 79, 13594–13605.
[28] Ito, T., Mukaigawa, J., Zuo, J., Hirabayashi, Y., Mitamura, K.
and Yasui, K. (1996) Cultivation of hepatitis C virus in primary
hepatocyte culture from patients with chronic hepatitis C results
in release of high titre infectious virus. J. Gen. Virol. 77 (Pt 5),
1043–1054.
